Skip to main content
Everest Medicines Limited logo

Everest Medicines Limited — Investor Relations & Filings

Ticker · 1952 LEI · 3003005FQADBCG83AX84 HKEX Manufacturing
Open in API
Filings indexed 313 across all filing types
Latest filing 2026-02-05 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1952

About Everest Medicines Limited

http://www.everestmedicines.com

Everest Medicines Limited is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines. The company focuses on licensing-in and advancing therapies to address critical unmet medical needs, primarily targeting patients across Greater China and other Asian Pacific markets. Its commercialized portfolio includes products such as XERAVA (eravacycline), approved for treating complicated intra-abdominal infections (cIAI).

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued shares, and share options (share option schemes). This type of filing is a standard regulatory requirement for companies listed on the HKEX to report monthly changes in securities, which falls under the category of 'Share Issue/Capital Change' (SHA).
2026-02-05 English
VOLUNTARY ANNOUNCEMENT AGREEMENT WITH MICOT TO COMMERCIALIZE MT1013 IN GREATER CHINA AND OTHER ASIAN MARKETS
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement regarding a strategic licensing agreement between Everest Medicines and Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize a drug (MT1013). It details the nature of the agreement, payment obligations, and the strategic rationale for the partnership. Since this is a corporate announcement regarding a business development/licensing deal that does not fit into specific categories like M&A (which usually implies a takeover or merger of entities) or other financial reporting categories, it is best classified as a general regulatory filing (RNS).
2026-02-05 English
Notification Letter to Registered Shareholders - Virtual Meeting Arrangements for the Extraordinary General Meeting
AGM Information Classification · 1% confidence The document is a notification letter sent to shareholders regarding the logistics and virtual meeting arrangements for an upcoming Extraordinary General Meeting (EGM). It provides instructions on how to attend, participate, and vote online. This type of communication is a standard proxy-related notification sent to shareholders to facilitate their participation in a corporate meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-02-03 English
Documents on Display
Regulatory Filings Classification · 1% confidence The document is a short announcement from the Hong Kong Stock Exchange (HKEX) regarding 'Continuing Connected Transactions' and 'Non-exempted Connected Transactions' for Everest Medicines Limited. It provides links to specific agreements and schemes rather than being the full report itself. Given the nature of the announcement regarding corporate transactions and the regulatory context, it fits best under the general regulatory filing category.
2026-02-03 English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON TUESDAY, 24 FEBRUARY 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Form of Proxy' for an Extraordinary General Meeting (EGM) of Everest Medicines Limited. It provides shareholders with the ability to appoint a proxy to vote on specific resolutions (such as the Commercialization Service Agreement) on their behalf. This type of document is standard material sent to shareholders to solicit their votes for a meeting, which falls under the category of Proxy Solicitation & Information Statement.
2026-02-03 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Extraordinary General Meeting' (EGM) issued by Everest Medicines Limited. It outlines the agenda, proposed resolutions (including commercialization agreements and share schemes), and procedural instructions for shareholders to attend and vote. This document is a formal solicitation of shareholder action and information regarding an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.